Status: Recruiting
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.
Participants needed: 48
Trial details
Phase: Phase 1Age: 19+Biological sex: FemaleType: InterventionalSponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsUpdated: Jul 2, 2026Locations: 2
Eligibility criteria
For the HIV- patient cohort only: patients with high-grade cervical intraepithel... [+12]
Patients with high-grade cervical intraepithelial lesions (CIN2/3) that are HPV1... [+18]